Lead sponsor
TauRx Therapeutics Ltd
11 Alzheimer’s disease and related dementias trials led. Source: ClinicalTrials.gov, as of July 21, 2026.
11
Trials led
0
Ongoing
3,920
Total enrollment
378
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 1
2
Phase 2
3
Phase 3
5
Not applicable
1
Trials by status
Completed
8
Terminated
2
Unknown
1
Trials led
TrialEligibility highlightPhaseStatusEnrollment
Open-Label Study of Leuco-methylthioninium Bis(Hydromethanesulfonate) (LMTM) in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)Multiple dementia etiologiesPh 3Terminated913
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's DiseaseAlzheimer's diseasePh 3Completed891
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's DiseaseAlzheimer's diseasePh 3Completed800
Safety and Efficacy of TRx0237 in Subjects With Alzheimer's Disease Followed by Open-Label TreatmentMCI due to ADPh 3Completed598
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)MMSE ≥20Ph 3Completed220
Safety Study of TRx0237 in Patients Already Taking Medications for Mild and Moderate Alzheimer's DiseaseAlzheimer's diseasePh 2Terminated9
TRx0237 for the Treatment of Early and Mild-Moderate Alzheimer's Diseasemild-to-moderate ADN/AUnknownnot disclosed